A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination
Enrolling by invitation · NCT07330440 · Registry updated 2026-01-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination | DNA Virus Infections, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Herpesviridae infectious disease, Infections, Male Urogenital Diseases, Urogenital Diseases, female reproductive system disorder, genital herpes, herpes simplex infectious disease, infectious disease, male reproductive system disorder, sexually transmitted disease, viral infectious disease, viral sexually transmitted disease | Enrolling by invitation | Phase 1 | 2026-01-09 | NCT07330440 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Changchun BCHT Biotechnology Co. | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Jishuitan Hospital | Beijing | China | 4 |